Business Parks & Science Centres

 
 
 

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5687 | Ordered by Date (descending)
1 2 3 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cevec–SEVERAL: investment, 201904 financing round Series D from new + existing investors 2019-04-16
Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk 2019-04-12
Evotec–Indivumed: cancer drug discovery, 201904– collab strategic precision medicine for new colorectal cancer drugs 2019-04-11
DKSH–Bruker Corp: analytical instruments, 201904– distribution excl extension for Bruker AXS products by DKSH in China 2019-04-09
Probiodrug–SEVERAL: investment, 201904 private placement €8.2m with 4.1m new shares at €2m led by Claus Christiansen et al. 2019-04-09
Phenex–Helmholtz: drug research, 201904– collab joint research in NASH + liver cancer metabolism with Heikenwälder Group at DKFZ 2019-04-05
AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France 2019-04-03
AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF 2019-04-03
AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes 2019-04-03
AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax 2019-04-03
AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology 2019-04-03
AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures 2019-04-03
Dyne Therapeutics–Atlas Venture: investment, 201904 financing round Series A totalling $50m incl founding investor Atlas Venture 2019-04-03
Dyne Therapeutics–Forbion: investment, 201904 financing round Series A totalling $50m incl co-investor Forbion 2019-04-03
Dyne Therapeutics–MPM Capital: investment, 201904 financing round Series A totalling $50m incl co-investor MPM Capital 2019-04-03
Dyne Therapeutics–SEVERAL: investment, 201904 financing round Series A $50m from founding investor Atlas Venture plus Forbion + MPM Capital 2019-04-03
LabCorp–Qiagen: molecular companion diagnostics, 201904– collab LabCorp joins Qiagen’s Day-One Lab Readiness program 2019-04-03
Rave LLC–Bruker Corp: investment, 201904 acquisition €na by Bruker 2019-04-03
Chr Hansen–Lonza: live biotherapeutics, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments 2019-04-02
Immunic–Rx Communications: public relations, 201904 service existent by Rx Communications Group 2019-04-02
Khloris Biosciences–Bayer: investment, 201904 seed financing €na from Leaps by Bayer 2019-04-02
IFM Therapeutics–Novartis: investment, 201904– acquisition 100% of IMF Tre for upfront payment + milestones ANNOUNCED 2019-04-01
Bayer–ProteoNic: rec protein production technology, 201903– license non-excl €na to use 2G UNic technology to boost rec protein production 2019-03-28
Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA 2019-03-28
Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA 2019-03-28
Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners 2019-03-28
Cytena–High-Tech Gründerfonds: investment, 201903 financing round Series A totalling €3.m incl HTGF + two private investors 2019-03-26
Cytena–SEVERAL: investment, 201903 financing round Series A €3.m from HTGF + two private investors 2019-03-26
Evotec–Mark Foundation: investment, 201903–202102 research funding for two years €na by Mark Foundation with potential financial returns 2019-03-26
Menarini–Curetis: molecular diagnostics, 201903– distribution excl long-term of Unyvero platform + cartridges in Europe by Menarini Diagnostics 2019-03-26
Hookipa–SEVERAL: investment, 201903– IPO up to $86.3m at Nasdaq FILED 2019-03-22
Atlatl–Miltenyi Biotec: CliniMACSProdigy platform, 201903– collab co-founding of Atlatl-Macs Center for Gene + Cell Therapy in Shanghai 2019-03-20
Oncimmune–Qiagen: investment, 201903 up to 1.34% shareholding for Qiagen after Oncimmune’s acquisition of Protagen 2019-03-19
Protagen–Oncimmune: investment, 201903 acquisition of Portagen for up to £4.11m in up to 2.636m ordinary shares 2019-03-19
Arxspan–Bruker Corp: investment, 201903 acquisition €na of Arxspan LLC by Bruker Corp 2019-03-14
Snipr Biome–Life Sciences Partners: investment, 201903 financing round Series A totalling $50m incl co-lead investor LSP 2019-03-11
Snipr Biome–Lundbeck: investment, 201903 financing round Series A totalling $50m incl existing + co-lead investor Lundbeckfonden Emerge 2019-03-11
Snipr Biome–North-East Family Office: investment, 201903 financing round Series A totalling $50m incl co-investor North-East Family Office 2019-03-11
Snipr Biome–SEVERAL: investment, 201903 financing round Series A $50m co-led by Lundbeckfonden Emerge + Life Sciences Partners 2019-03-11
Snipr Biome–Wellington Partners: investment, 201903 financing round Series A totalling $50m incl co-investor Wellington Partners 2019-03-11
Qiagen–Tecan: lab automation, 201903– collab direct supply of Tecan Fluent workstation for sample to labs using QuantiFeron-TB Gold Plus test 2019-03-08
Gilde Investment–SEVERAL: investment, 201903 final close €200m Gilde Healthcare Service III fund incl PGGM/PF Zorg en Welzijn + Rabo Corp Investments 2019-03-07
BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m 2019-03-05
Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB 2019-03-05
abcr GmbH–Enzymicals: enzymes, 201903– collab distribution expansion ww sale of all catalogue products of Enzymcials by acbr 2019-03-04
NovaGo Therapeutics–Neurimmune: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor + strategic partner Neurimmune 2019-03-04
NovaGo Therapeutics–Pureos Bioventures: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor Pureos Bioventures 2019-03-04
NovaGo Therapeutics–SEVERAL: investment, 201903 financing round Series A CHF10m co-led by Pureos Bioventures + Neurimmune 2019-03-04
CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility 2019-03-01
Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum 2019-02-28
Sarepta–Centogene: molecular diagnostics, 201902–202002 collab service identifying DMD patients in MENA region by Centogene 2019-02-28
Versum Materials–Merck (DE): investment, 201902– unsolicited all-cash offer at $48/share by Merck 2019-02-27
Anaveon–Novartis: investment, 201902 financing round Series A totalling CHF35m incl co-investor Novartis Venture Fund 2019-02-26
Anaveon–SEVERAL: investment, 201902 financing round Series A CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Anaveon–Wellcome Trust: investment, 201902 financing round Series A totalling CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Hookipa–Invus Group: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Invus 2019-02-26
Hookipa–Redmile Group: investment, 201902 financing round Series D totalling €33.2m incl new + lead investor Redmile Group 2019-02-26
Hookipa–Samsara BioCapital: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Samsara BioCapital 2019-02-26
Hookipa–SEVERAL: investment, 201902 financing round Series D €33.2m ($37.4m) led by Redmile Group + incl Invus + Samsara Capital et al. 2019-02-26
Samsara Therapeutics–Apollo Ventures: investment, 201902 seed financing round totalling €1m incl lead investor Apollo Ventures 2019-02-26
Samsara Therapeutics–Evotec: medicinal chemistry, 201902 supply service existent compound optimisationn by Evotec 2019-02-26
Samsara Therapeutics–SEVERAL: investment, 201902 seed financing round €1m led by Apollo Ventures 2019-02-26
General Electric–Danaher: investment, 201902– acquisition $21.4b in cash of biopharma business of GE Life Sciences ANNOUNCED 2019-02-25
Roche–Citigroup: financial services, 201902 supply Citi financial advisor to Roche with regard to acquisition of Spark by Roche 2019-02-25
Roche–Davis Polk & Wardwell: legal services, 201902 supply service legal advisor to Roche w regard acquisition of Spark Therapeutics 2019-02-25
Spark Therapeutics–Centerview Partners: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Cowen: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Goodwin Procter: legal services, 201902 supply legal counsel to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Roche: investment, 201902– acquisition $4.3b cash tender offer for all shares at $114.5/share ANNOUNCED 2019-02-25
Alchemist Accelerator–BASF: investment, 201902 BASF Venture Capital invests $2m + becomes Limited Partner 2019-02-20
Calypso Biotech–ABP (NL): investment, 201902 financing round Series A totallling €20m incl co-lead investor Inkef Capital 2019-02-20
Calypso Biotech–Gilde Investment: investment, 201902 financing round Series A totallling €20m incl co-lead investor Gilde Healthcare 2019-02-20
Calypso Biotech–JnJ: investment, 201902 financing round Series A totallling €20m incl co-investor JnJ Innovation JJDC 2019-02-20
Calypso Biotech–Merck (DE): investment, 201902 financing round Series A totallling €20m incl co- + founding investor M Ventures 2019-02-20
Calypso Biotech–SEVERAL: investment, 201902 financing round Series A €20m co-led by Gilde Healthcare + Inkef Capital 2019-02-20
Evotec–Helmholtz: antibiotics, 201902– collab development with initial focus on cystobactamids with Helmholtz HZI Braunschweig 2019-02-20
CRISPR Therapeutics–StrideBio: AAV vectors, 201902– collab expansion €na of developm + license option usingStrideBio’s vectors for CRISPR therapies 2019-02-19
Gain Therapeutics–Fondazione Centenario BancaStato: investment, 201902 financing round Series A totalling €2.5m incl €400k from TiVenture SA 2019-02-19
Gain Therapeutics–Helsinn: investment, 201902 financing round Series A totalling €2.5m incl €1m from new investor Helsinn Investment Fund SA 2019-02-19
Gain Therapeutics–SEVERAL: investment, 201902 financing round Series A €2.5m from VitaTech + Helsinn Investment Fund + TiVenture 2019-02-19
Gain Therapeutics–VitaTech: investment, 201902 financing round Series A totalling €2.5m incl €1.1m from new investor VitaTech SA 2019-02-19
Qiagen–Curetis: bioinformatics, 201902– license excl to use ARESdb for general bioinformatics research offerings + services for AMR research 2019-02-18
S-Biomedic–DSM: investment, 201902 financing round Series A 2nd closing totalling €2m incl new investor DSM Venturing 2019-02-18
S-Biomedic–SEVERAL: investment, 201902 financing round Series A 2nd closing €2m from new investor DSM Venturing + existing investor investiere.ch 2019-02-18
S-Biomedic–Verve Capital Partners: investment, 201902 financing round Series A 2nd closing totalling €2m incl existing investor investiere.ch 2019-02-18
Arvelle Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling $180m incl investor Andera Partners 2019-02-14
Arvelle Therapeutics–BRV Capital: investment, 201902 financing round Series A totalling $180m incl investor BRV Capital Management 2019-02-14
Arvelle Therapeutics–H.I.G. Capital: investment, 201902 financing round Series A totalling $180m incl investor H.I.G. BioHealth Partners 2019-02-14
Arvelle Therapeutics–Life Sciences Partners: investment, 201902 financing round Series A totalling $180m incl lead investor LSP 2019-02-14
Arvelle Therapeutics–NovaQuest Capital: investment, 201902 financing round Series A totalling $180m incl investor NovaQuest Capital Management 2019-02-14
Arvelle Therapeutics–Sam Brown: public relations, 201902 service existent by Sam Brown Inc 2019-02-14
Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate 2019-02-14
Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals 2019-02-14
Novartis–AbCellera: therapeutic antibodies, 201902– collab discovery use of AbCellera technology + screening for up to ten targets 2019-02-14
Plasmion–Bavaria (govt): investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–High-Tech Gründerfonds: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–PERSON: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–SEVERAL: investment, 201902 financing round almost €1m from HTGF + BayBG + business angel 2019-02-14
Boehringer–IBM: blockchain technology, 201902– collab to integrate blockchain technology into clinical trials of BI Canada + IBM Canada 2019-02-12
1 2 3 ... 55 56 57  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px

» top